Company Overview and News

 
NEC, Samsung to team up on developing, marketing 5G mobile network systems

8h japantimes.co.jp
NEC Corp. and Samsung Electronics Co. will tie up in the development and global marketing of next-generation telecommunication base stations for mobile phone carriers, sources close to the matter said Sunday.
9437 BC94 NTDMF SMSN DCM SMSD

 
Samsung planning to develop AI-powered multi-device system

10h financialexpress
With Artificial Intelligence (AI) pushing the frontiers of communication technology, Samsung Electronics is planning to develop a multi-device platform — a variety of AI-enabled devices that communicate seamlessly with each other — to make experiences more personal and relevant.
BC94 SMSN SMSD

 
Samsung aims at 10% African growth despite rising competition

2018-10-19 theedgemarkets
(Ot 19): Samsung Electronics Co is targeting an annual 10% increase in revenue from Africa over the next decade, even as competition from cheaper consumer devices intensifies.
BC94 SMSN SMSD

 
(LEAD) Seoul shares rebound on institutional buying

2018-10-19 english.yonhapnews.co.kr
SEOUL, Oct. 19 (Yonhap) -- South Korean stocks bounced back Friday as institutions bought blue chip stocks to offset foreign-led selling. The local currency strengthened against the U.S. dollar.
BC94 SMSN SMSD

 
Seoul shares rebound on institutional buying

2018-10-19 english.yonhapnews.co.kr
SEOUL, Oct. 19 (Yonhap) -- South Korean stocks bounced back Friday as institutions bought blue chip stocks to offset foreign-led selling. The local currency strengthened against the U.S. dollar.
BC94 SMSN SMSD

 
Samsung showcases new display tech in China

2018-10-19 english.yonhapnews.co.kr
SEOUL, Oct. 19 (Yonhap) -- Samsung Display Co. on Friday said it hosted the Samsung OLED Forum 2018 in China earlier this week, where it invited Chinese business partners to showcase its latest technological achievements.
BC94 SMSN SMSD

 
Samsung opens new AI center in Montreal

2018-10-19 english.yonhapnews.co.kr
SEOUL, Oct. 19 (Yonhap) -- Samsung Electronics Co. on Friday said it has opened a new artificial intelligence (AI) research center in Montreal, which marks the seventh of its kind around the globe.
BC94 SMSN SMSD

 
Seoul shares fall on hawkish Fed, BOK rate freeze

2018-10-18 english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- South Korean stocks lost ground Thursday as rising odds of interest rate hikes in the United States weighed on investor sentiment, while the Bank of Korea froze the key interest rate. The local currency fell against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
(LEAD) Seoul shares fall on hawkish Fed, BOK rate freeze

2018-10-18 english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- South Korean stocks lost ground Thursday as rising odds of interest rate hikes in the United States weighed on investor sentiment, while the Bank of Korea froze the key interest rate. The local currency fell against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

1
Samsung tops U.S. computer reliability report

2018-10-18 english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- Samsung Electronics Co.'s computers are considered to be more reliable compared to its archrival Apple Inc., U.S. computer repair service provider RESCUECOM said in its latest report.
AAPL BC94 SMSN SMSD

 
Samsung introduces new 7-nanometer process utilizing EUV tech

2018-10-18 koreaherald
Samsung Electronics Co. on Thursday announced that it has started the production of foundry chips using the 7-nanometer Low Power Plus process that utilizes the extreme ultraviolet lithography technology for the first time in the industry. "The commercialization of its newest process node, 7LPP gives customers the ability to build a full range of exciting new products that will push the boundaries of applications, such as 5G, artificial intelligence, enterprise and hyperscale data center, IoT, automotive and networking," the company said.
BC94 SMSN SMSD

 
Samsung introduces new 7-nanometer process utilizing EUV tech

2018-10-18 english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- Samsung Electronics Co. on Thursday announced that it has started the production of foundry chips using the 7-nanometer Low Power Plus (LPP) process that utilizes the extreme ultraviolet (EUV) lithography technology for the first time in the industry.
BC94 SMSN SMSD

3
The Disconnect Between Memory Chip Output And Processing Equipment Sales: Part 2, Equipment

2018-10-17 seekingalpha
DRAM capex spend pushouts by Samsung Electronics were largely to blame for a QoQ revenue drop by Lam Research in the recent September quarter.
LRCX SSNLF HXSCF MU AMAT BC94 SMSN HXSCL SMSD

 
Seoul shares rise on upbeat U.S. earnings

2018-10-17 english.yonhapnews.co.kr
SEOUL, Oct. 17 (Yonhap) -- South Korean stocks advanced Wednesday as strong earnings data and economic indicators from the United States boosted investor sentiment. The local currency strengthened against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
(LEAD) Seoul shares rise on upbeat U.S. earnings

2018-10-17 english.yonhapnews.co.kr
SEOUL, Oct. 17 (Yonhap) -- South Korean stocks advanced Wednesday as strong earnings data and economic indicators from the United States boosted investor sentiment. The local currency strengthened against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...